BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.